New immunotherapy DF9001 targets Hard-to-Treat cancers
NCT ID NCT05597839
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find the best dose, with early signs of tumor shrinkage also measured.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DF9001 (an immunotherapy that targets natural killer cells) and pembrolizumab (Keytruda, an anti-PD-1 immunotherapy)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that express EGFR, potentially shrinking tumors or slowing their growth.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped, and it is not yet proven to be safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMR Kansas City
Kansas City, Missouri, 64114, United States
-
Banner MD Anderson
Gilbert, Arizona, 85234, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Rutgers
New Brunswick, New Jersey, 08903, United States
-
UC Irvine Medical Center
Irvine, California, 92617, United States
-
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Louisville Hospital
Louisville, Kentucky, 40202, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States